Elagolix + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome
Trial Timeline
Aug 12, 2019 → Feb 10, 2021
NCT ID
NCT03951077About Elagolix + Placebo
Elagolix + Placebo is a phase 2 stage product being developed by AbbVie for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03951077. Target conditions include Polycystic Ovary Syndrome.
What happened to similar drugs?
3 of 14 similar drugs in Polycystic Ovary Syndrome were approved
Approved (3) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03951077 | Phase 2 | Completed |
| NCT03886220 | Approved | Completed |
| NCT00619866 | Phase 2 | Completed |
Competing Products
20 competing products in Polycystic Ovary Syndrome